Data / Research funding / Pneumonia & Influenza
Pneumonia & Influenza: 548 NIH awards ($436.8M) to 206 organizations
548 NIH awards ($436.8M) in the NIH spending category Pneumonia & Influenza, to 206 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 548 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Disordered Proteostasis as a Driver of Disease in the Aging Lung | NIH | National Institute on Aging | 2021 to 2024 | $8,161,610 | July 1, 2015 | March 31, 2025 | BUDINGER, GR SCOTT | reporter.nih.gov |
| 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,715,477 | September 23, 2019 | August 31, 2025 | LEVITT, JOSEPH ERIC | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| Development of ureadepsipetides for drug-resistant infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,597,406 | December 17, 2018 | November 30, 2024 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Sex and Age Differences in Immunity to Influenza (SADII) | NIH | National Institute on Aging | 2021 to 2022 | $3,417,361 | September 30, 2018 | May 31, 2023 | KLEIN, SABRA L. | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,407,387 | January 7, 2019 | December 31, 2023 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,343,171 | January 9, 2019 | December 31, 2024 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,332,208 | December 14, 2018 | November 30, 2024 | TING, JENNY P | reporter.nih.gov |
| Uncovering associations of variant infection with COVID-19 disease severity in children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $3,214,599 | January 1, 2021 | June 30, 2023 | CHIU, CHARLES YEN | reporter.nih.gov |
| Universal room temperature stable influenza nanovaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,103,165 | January 24, 2019 | December 31, 2024 | NARASIMHAN, BALAJI | reporter.nih.gov |
| Novel delivery platform and antigen design for an effective COVID-19 vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,066,236 | August 11, 2020 | July 31, 2027 | MITTAL, SURESH K | reporter.nih.gov |
| Increasing Availability of Emulsion Adjuvants via Synthetic Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,996,311 | August 30, 2022 | August 29, 2025 | KEMPINSKI, CHASE | reporter.nih.gov |
| Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,853,123 | January 8, 2019 | December 31, 2025 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Microarray Patch for Broadly Protective Seasonal Influenza Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,845,449 | April 9, 2021 | March 31, 2024 | KOSUDA, KATHRYN | reporter.nih.gov |
| Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,605,499 | August 25, 2020 | May 31, 2023 | BILSEL, PAMUK | reporter.nih.gov |
| Innate Immune Clearance of Host-Adapted Pulmonary Pathogens | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,586,182 | January 11, 2017 | November 30, 2024 | PRINCE, ALICE S | reporter.nih.gov |
| Epitope focusing by molecular grafting of subdominant epitopes to achieve a universal-influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,528,765 | July 22, 2019 | June 30, 2024 | SCHMIDT, AARON GREGORY | reporter.nih.gov |
| Pneumonia Biology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,516,358 | January 11, 2017 | December 31, 2024 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Effects of obesity on the dynamics of Influenza transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,430,473 | June 10, 2019 | May 31, 2025 | SCHULTZ-CHERRY, STACEY L | reporter.nih.gov |
| Does repeated influenza vaccination constrain influenza immune responses and protection? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,405,849 | July 3, 2019 | June 30, 2025 | FOX, ANNETTE | reporter.nih.gov |
| Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,388,592 | September 21, 2016 | May 31, 2025 | CHAPMAN, HAROLD A | reporter.nih.gov |
| Multivalent nanocluster universal influenza vaccine given by microneedle patch | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,311,653 | February 12, 2019 | January 31, 2026 | WANG, BAOZHONG | reporter.nih.gov |
| Evaluation of pregnancy on vaccine-induced immunity and protection in a pre-clinical model of RSV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,306,179 | September 24, 2020 | August 31, 2025 | NORRIS, KAREN A | reporter.nih.gov |
| Improving predictive capacity of models for universal influenza vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,303,623 | August 1, 2020 | July 31, 2025 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Syrian hamsters as an animal model for influenza virus research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,277,423 | September 2, 2020 | August 31, 2025 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,232,574 | June 20, 2018 | May 31, 2025 | KOO, SOPHIA | reporter.nih.gov |
| CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,227,740 | April 1, 2014 | August 1, 2022 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Universal T cell targeted influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,225,857 | September 1, 2020 | August 31, 2025 | HOFT, DANIEL F. | reporter.nih.gov |
| Targeting RIPK3 in Flu-Associated Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,222,961 | September 18, 2019 | August 31, 2025 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,153,664 | March 22, 2019 | April 30, 2024 | PERLIN, DAVID S | reporter.nih.gov |
| Task A44: Ferret Models for the Evaluation of Universal Influenza Vaccines and Vaccine Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,150,482 | August 13, 2020 | May 9, 2022 | WALTERS, KEVIN | reporter.nih.gov |
| Dynamic regulatory network models of human response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,128,800 | August 17, 2020 | October 3, 2022 | MARAZZI, IVAN | reporter.nih.gov |
| Development of a Universal Influenza Vaccine Against Influenza A and B Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,044,468 | November 12, 2018 | October 31, 2024 | GILL, HARVINDER SINGH | reporter.nih.gov |
| IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,042,193 | July 12, 2022 | June 30, 2024 | HUTCHINS, JEFF T | reporter.nih.gov |
| Novel lung resident interstitial macrophage subset with distinct localization and polarization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,035,067 | January 1, 2019 | December 31, 2023 | KHANNA, KAMAL MOHAN | reporter.nih.gov |
| Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,021,352 | February 6, 2019 | January 31, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,019,810 | August 20, 2018 | March 31, 2024 | LINKE, LYNDSEY | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating SARS-CoV-2 virus related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | March 6, 2021 | February 29, 2024 | CRAIGO, JODI K | reporter.nih.gov |
| Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | August 1, 2019 | July 31, 2024 | ROEMER, TERRY | reporter.nih.gov |
| Strain-Independent Therapeutic Antibodies for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,999,271 | July 1, 2014 | January 31, 2023 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,988,078 | June 22, 2020 | June 30, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,977,893 | February 22, 2017 | January 31, 2024 | HARDING, CHRISTIAN | reporter.nih.gov |
| CMC of Peptide Formulation for the Treatment of ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,967,733 | June 1, 2022 | May 31, 2025 | CASTILLO, GERARDO M. | reporter.nih.gov |
| Novel Influenza nano vaccines for broad cross protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,941,278 | May 15, 2012 | June 30, 2025 | WANG, BAOZHONG | reporter.nih.gov |
| PROmotion of COVid-19 VA(X)ccination in the Emergency Department - PROCOVAXED | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,899,293 | May 24, 2021 | March 10, 2025 | RODRIGUEZ, ROBERT | reporter.nih.gov |
| Alpha(v) integrins and germinal center B cell responses to viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,880,880 | August 1, 2020 | July 31, 2024 | ACHARYA, MRIDU | reporter.nih.gov |
| Single cell molecular analysis of influenza vaccine responses in elderly individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,879,797 | March 1, 2019 | February 28, 2025 | KALAMS, SPYROS A | reporter.nih.gov |
| Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,837,793 | June 21, 2019 | May 31, 2024 | PARDI, NORBERT | reporter.nih.gov |
| Influenza virus receptors on human airway epithelial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,818,983 | September 3, 2015 | July 31, 2025 | PAULSON, JAMES C | reporter.nih.gov |
| DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,796,584 | April 24, 2020 | March 31, 2023 | JONES, CHARLES HOUSTON | reporter.nih.gov |
| Mechanisms of dysregulated immunity with aging | NIH | National Institute on Aging | 2021 to 2023 | $1,757,769 | July 15, 2007 | December 31, 2024 | DENG, JANE C | reporter.nih.gov |
| Role of mitophagy in age-related respiratory and vascular diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,755,000 | January 1, 2021 | October 31, 2023 | GOLDSTEIN, DANIEL ROBERT | reporter.nih.gov |
| Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,737,261 | May 1, 2020 | August 31, 2023 | LEE, JAE WOO | reporter.nih.gov |
| A point-of-care device using Single Molecule Array (Simoa) to measure viral antigens in nasal swabs, saliva, and blood | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 | $1,705,157 | September 22, 2022 | August 31, 2025 | DUFFY, DAVID C | reporter.nih.gov |
| High-resolution single cell profiling of vaccine responsiveness in the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,687,224 | February 14, 2019 | January 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| FcRn-Targeted Mucosal Vaccination Against Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,633,734 | May 14, 2019 | April 30, 2025 | ZHU, XIAOPING | reporter.nih.gov |
| Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,619,208 | January 16, 2018 | December 31, 2023 | FOX, CHRISTOPHER B | reporter.nih.gov |
| Integrated Analysis of Microbial and Genomic data in Obstructive Lung Disease (I AM GOLD) Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,595,582 | September 15, 2019 | July 31, 2025 | HUANG, LAURENCE | reporter.nih.gov |
| Regulation of the IgG Fc domain repertoire | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,578,892 | January 15, 2019 | December 31, 2024 | WANG, TAIA | reporter.nih.gov |
| T resident memory in the lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,565,922 | April 1, 1998 | October 31, 2023 | HARTY, JOHN T | reporter.nih.gov |
| Triggering germline-encoded broadly neutralizing antibody responses against influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,561,851 | August 19, 2020 | July 31, 2025 | LINGWOOD, DANIEL | reporter.nih.gov |
| Development of RespiraClear for targeted mucosal treatment of RSV infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,549,957 | August 19, 2019 | April 30, 2024 | CONE, RICHARD | reporter.nih.gov |
| Transcriptomic Signatures of Influenza Vaccine Responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,540,548 | January 17, 2018 | December 31, 2024 | POLAND, GREGORY A. | reporter.nih.gov |
| Structure-function analysis of type IVB secretion systems | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,535,493 | June 10, 2019 | May 31, 2025 | CAPARON, MICHAEL G. | reporter.nih.gov |
| Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,531,885 | February 11, 2021 | November 30, 2023 | PAMULA, VAMSEE K. | reporter.nih.gov |
| Targeting ABL kinases to regulate epithelial cell plasticity and regeneration following injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,520,108 | June 1, 2020 | April 30, 2024 | PENDERGAST, ANN MARIE | reporter.nih.gov |
| The influence of evolutionary landscapes on protective antibody development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,518,710 | January 24, 2019 | December 31, 2024 | WHITEHEAD, TIMOTHY ANDREW | reporter.nih.gov |
| Dynamics of the protective vaccine-induced human influenza neuraminidase B cell response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,517,506 | September 16, 2019 | August 31, 2025 | KOBIE, JAMES J | reporter.nih.gov |
| Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,495,366 | January 16, 2018 | December 31, 2023 | SZILAGYI, PETER G | reporter.nih.gov |
| Identifying host and viral correlates for coronavirus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,493,658 | June 15, 2020 | May 31, 2025 | JOHNSON, BRYAN A | reporter.nih.gov |
| Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,492,136 | June 7, 2019 | August 31, 2023 | DE FIGUEIREDO, PAUL | reporter.nih.gov |
| Impact of Heightened UPR Activation on Inflammasome Responses to Influenza and Secondary Streptococcus pneumoniae Infection in Aged Lung | NIH | National Institute on Aging | 2021 to 2022 | $1,491,600 | May 1, 2018 | April 30, 2024 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| A rationally-designed, live-attenuated RSV vaccine for the elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,474,810 | August 16, 2017 | June 30, 2025 | MUELLER, STEFFEN | reporter.nih.gov |
| Immunotherapy of KPC Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,459,263 | August 1, 2020 | July 31, 2025 | KOLLS, JAY K | reporter.nih.gov |
| Mechanisms of actin cytoskeleton modulation by Pneumoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,425,119 | June 1, 2018 | May 31, 2024 | DUTCH, REBECCA E. | reporter.nih.gov |
| Lung-resident antibacterial heterotypic immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,423,673 | July 1, 2015 | June 30, 2025 | MIZGERD, JOSEPH P | reporter.nih.gov |
| Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,422,000 | August 1, 2020 | July 31, 2025 | NIZET, VICTOR | reporter.nih.gov |
| Lung-on-a-Chip Disease Models for Efficacy Testing | NIH | National Heart, Lung, and Blood Institute | 2021 | $1,413,750 | September 1, 2017 | October 31, 2022 | INGBER, DONALD E | reporter.nih.gov |
| Messenger RNA capping and methylation in pneumoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,407,102 | December 1, 2010 | January 31, 2025 | LI, JIANRONG | reporter.nih.gov |
| Germline targeting influenza immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,394,075 | August 10, 2017 | July 31, 2024 | NEMAZEE, DAVID | reporter.nih.gov |
| Unique ADP-ribosylating and vacuolating properties of Mycoplasma pneumoniae CARDS toxin trigger airway inflammation and disease progression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,368,330 | March 1, 2019 | February 28, 2026 | KANNAN, THIRUMALAI RENGASAMY | reporter.nih.gov |
| Understanding hypermucoviscosity in Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,358,649 | July 16, 2020 | September 30, 2024 | MILLER, VIRGINIA L | reporter.nih.gov |
| Multiscale modeling of influenza vaccination strategies for optimal T cell immunity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,349,033 | September 1, 2018 | May 31, 2024 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Epidemiology, transmission and immunology of COVID-19 in nursing home residents | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,332,423 | July 23, 2020 | November 30, 2023 | CANADAY, DAVID H | reporter.nih.gov |
| Molecular mechanism of cardiac inflammation and dysfunction in Pseudomonas aeruginosa infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,319,211 | July 1, 2019 | June 30, 2025 | RAJARAM, MURUGESAN | reporter.nih.gov |
| Emerging methods and applications for test-negative studies of of infectious disease interventions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,313,010 | July 17, 2020 | June 30, 2025 | JEWELL, NICHOLAS P | reporter.nih.gov |
| Immunotherapy for acute lung injury secondary to influenza | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,310,316 | April 1, 2020 | March 31, 2025 | KNIGHT III, PAUL R | reporter.nih.gov |
| Cell surface biogenesis in Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,290,258 | January 1, 2019 | December 31, 2024 | RUDNER, DAVID Z | reporter.nih.gov |
| A host-dependent mechanism controlling influenza virus infection by suppressing viral RNA synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,271,250 | January 10, 2019 | December 31, 2023 | MARAZZI, IVAN | reporter.nih.gov |
| A Regulatory Cascade that Controls Pneumococcal Capsule Biosynthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,270,445 | August 23, 2019 | July 31, 2024 | ULIJASZ, ANDREW T | reporter.nih.gov |
| Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM) | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $1,248,392 | March 10, 2021 | July 31, 2022 | PARVEZ, MUHAMMAD F | reporter.nih.gov |
| Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,244,512 | June 18, 2018 | May 31, 2025 | RYTER, KENDAL | reporter.nih.gov |
| Impact of versican deficiency on the innate immune response to influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,232,686 | December 12, 2017 | November 30, 2023 | FREVERT, CHARLES WAYNE | reporter.nih.gov |
| Host nutrients permit immune evasion of NKT cell anti-bacterial responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,230,778 | January 17, 2018 | December 31, 2022 | KRONENBERG, MITCHELL | reporter.nih.gov |
| Deciphering the Role of Rgg in the Pneumococcal Signaling, Colonization and Virulence Portfolio | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,213,672 | May 23, 2019 | April 30, 2025 | HILLER, NATALIA LUISA | reporter.nih.gov |
| C-terminal proteolysis in the Pseudomonas aeruginosa cell envelope | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,212,063 | January 1, 2018 | December 31, 2024 | DARWIN, ANDREW J. | reporter.nih.gov |
| Loss of cellular identity after influenza virus infection and effects on pulmonary function | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,197,512 | July 1, 2018 | June 30, 2024 | HEATON, NICHOLAS S | reporter.nih.gov |
| Analyzing Adult Pneumococcal Vaccination Implementation in the Underserved | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,185,730 | June 1, 2020 | May 31, 2025 | SMITH, KENNETH J | reporter.nih.gov |
| The role of hepoxilin A3 in neutrophil breach of the Infected airway mucosa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,184,750 | February 8, 2012 | May 31, 2024 | HURLEY, BRYAN P | reporter.nih.gov |
| Macrophage Signaling Pathways in Acute Lung Injury and Resolution | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,180,500 | March 1, 2019 | February 29, 2024 | MANICONE, ANNE M. | reporter.nih.gov |
| Trafficking and function of macrophage subpopulations within the lung microenvironment during pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,171,522 | January 1, 2019 | December 31, 2024 | DOERSCHUK, CLAIRE M | reporter.nih.gov |
| Innate Immunity in Lung Infection-induced Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,170,976 | June 1, 2018 | May 31, 2025 | JEYASEELAN, SAMITHAMBY | reporter.nih.gov |
| Persistent Post-Viral State of Bacterial Pneumonia Susceptibility and Severity in Down Syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,166,250 | June 1, 2019 | May 31, 2024 | YEAGER, MICHAEL E. | reporter.nih.gov |
| A Microphysiological Mimicry of Human Lung-Bone Marrow Organ-Organ Crosstalk On-a-Chip | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,161,578 | April 1, 2021 | June 30, 2025 | HAJIPOURAN BENAM, KAMBEZ | reporter.nih.gov |
| Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,156,797 | August 22, 2019 | January 1, 2024 | WEITZ, JOSHUA | reporter.nih.gov |
| Development of a Universal Immunotherapeutic for Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,155,553 | March 14, 2019 | March 31, 2023 | HOLTSBERG, FREDERICK WAYNE | reporter.nih.gov |
| Mechanisms of host protection against pathogen-associated proteases in acute lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,142,264 | August 1, 2017 | December 31, 2022 | LEE, JANET SOJUNG | reporter.nih.gov |
| Mechanism for anti-interferon functions of influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,140,159 | June 20, 2019 | May 31, 2025 | SHI, YUAN | reporter.nih.gov |
| Human B1-like Cells and Pneumococcal Defense in the Elderly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,132,500 | February 1, 2019 | January 31, 2025 | ROTHSTEIN, THOMAS L | reporter.nih.gov |
| Sex Determines Age-related Changes in the Repertoire and Function of Natural Antibodies Protective against Streptococcus pneumoniae with Increasing Age | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,132,500 | September 21, 2020 | August 31, 2024 | HOLODICK, NICHOL ELIZABETH | reporter.nih.gov |
| Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,123,469 | August 15, 2017 | July 31, 2024 | DEGROOT, ANNE SEARLS | reporter.nih.gov |
| Influenza regulation of epithelial pneumococcal host defense. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,113,750 | September 10, 2020 | August 31, 2025 | HARROD, KEVIN S | reporter.nih.gov |
| Respiratory Syncytial Virus Targeting of the Human Airway Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,109,490 | December 1, 2011 | December 31, 2024 | PEEPLES, MARK E. | reporter.nih.gov |
| Developing a Novel E3 Ligase based Anti-inflammatory for ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,102,297 | February 1, 2022 | January 31, 2025 | MALLAMPALLI, RAMA K | reporter.nih.gov |
| Control of Influenza Infection by Lipid Mediators and Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,522 | January 10, 2018 | December 31, 2024 | HAHN, YOUNG S. | reporter.nih.gov |
| Regulation of Legionella pneumophila pathogenesis by the central eukaryotic metabolic checkpoint kinase Mechanistic Target of Rapamycin (MTOR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,095,000 | February 11, 2019 | January 31, 2025 | IVANOV, STANIMIR STEFANOV | reporter.nih.gov |
| HLA-DO / H2-O: modulation of MHC-II peptide diversity and Treg population control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,082,364 | December 12, 2017 | November 30, 2023 | STERN, LAWRENCE J. | reporter.nih.gov |
| Endothelial cell tropism in the pathogenesis and host response against influenza viruses - Resubmission 01 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,080,542 | December 8, 2017 | November 30, 2023 | MANICASSAMY, BALAJI | reporter.nih.gov |
| Characterization of a distinct NKT subset and its role in influenza responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,075,834 | May 1, 2018 | April 30, 2024 | ALBEROLA-ILA, JOSE | reporter.nih.gov |
| 2/1 Arrest Respiratory Failure due to Pneumonia (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,068,366 | September 15, 2019 | August 31, 2025 | DESAI, MANISHA | reporter.nih.gov |
| Innate-like BCR activity as a template for universal vaccination against influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,058,052 | June 1, 2018 | May 31, 2023 | LINGWOOD, DANIEL | reporter.nih.gov |
| Addressing unanticipated events for Intranasal Influenza H5 Vaccine Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,052,554 | August 8, 2022 | July 31, 2024 | ORTIZ, JUSTIN R. | reporter.nih.gov |
| Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,045,564 | June 20, 2017 | April 30, 2023 | TESTA, CHARLES | reporter.nih.gov |
| Influenza D Virus Entry and Tissue Tropism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,033,696 | September 21, 2018 | August 31, 2025 | LI, FENG | reporter.nih.gov |
| Controlling bactermic pneumococcal pneumonia with synthetic dominant-negative competence peptides | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,023,618 | April 1, 2019 | March 31, 2024 | LAU, GEE W | reporter.nih.gov |
| Oxidative Burst in Influenza and MRSA Co-infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,022,922 | May 22, 2013 | December 31, 2024 | SUN, KEER | reporter.nih.gov |
| Automated Surveillance of Overlapping Outbreaks and New Outbreak Diseases | NIH | National Library of Medicine | 2021 to 2023 | $1,008,755 | August 3, 2021 | July 31, 2025 | COOPER, GREGORY F. | reporter.nih.gov |
| Development of VLP vaccine for RSV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | February 15, 2014 | February 28, 2024 | BLANCO, JORGE C | reporter.nih.gov |
| Improved Influenza Vaccine Efficacy Through Infection Mimicry | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $999,900 | April 15, 2019 | January 31, 2022 | KOSUDA, KATHRYN | reporter.nih.gov |
| Influence of polysialic acid on leukocyte migration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $999,737 | June 1, 2018 | May 31, 2024 | STAMATOS, NICHOLAS MILTON | reporter.nih.gov |
| Therapeutic Antibody for RSV IIB | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $997,704 | February 1, 2016 | November 30, 2021 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Bacterial Cell Wall Composition and the Influence of Antibiotics | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $997,488 | September 1, 2016 | May 31, 2025 | CEGELSKI, LYNETTE S | reporter.nih.gov |
| In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $995,652 | August 20, 2018 | November 30, 2022 | CONE, RICHARD | reporter.nih.gov |
| Flu Dynamics COVID-19 Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $983,380 | July 28, 2020 | December 31, 2023 | GORDON, AUBREE L | reporter.nih.gov |
| LncRNA regulates lung inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $983,168 | September 1, 2019 | June 30, 2025 | JIN, YANG | reporter.nih.gov |
| MycoMEIA - Urine Diagnostic for Aspergillosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $976,576 | March 8, 2021 | February 28, 2023 | MARR, KIEREN A. | reporter.nih.gov |
| Balancing protective immunity and chronic sequelae by resident CD8 T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $966,944 | August 20, 2020 | December 31, 2021 | SUN, JIE | reporter.nih.gov |
| The role of sex in the life cycle and transmission of Pneumocystis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $965,843 | February 1, 2019 | January 31, 2024 | CUSHION, MELANIE T | reporter.nih.gov |
| The impact of dietary zinc deficiency on innate immunity to lung infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $954,119 | February 1, 2021 | January 31, 2025 | PALMER, LAUREN DISTERHOFT | reporter.nih.gov |
| Preclinical Pulmonary Fibrosis, an opportune rare disease cohort | NIH | National Heart, Lung, and Blood Institute | 2021 | $944,445 | August 1, 2020 | July 31, 2022 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| INFLUENZA-SPECIFIC IMMUNITY AND RESPONSES TO INACTIVATED INFLUENZA VACCINE IN INFANTS: EFFECT OF MATERNAL VACCINATION DURING PREGNANCY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $932,996 | June 18, 2020 | May 31, 2025 | WEINBERG, ADRIANA | reporter.nih.gov |
| The Role of Sex Dimorphism in Post-TBI Bacterial Pneumonia | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $928,637 | September 21, 2018 | August 31, 2025 | WAGENER, BRANT M | reporter.nih.gov |
| Regulation of IL10 production in CD8+ T cells during Flu infection by tyrosine kinase Itk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $921,550 | June 18, 2018 | May 31, 2024 | AUGUST, AVERY | reporter.nih.gov |
| B-1 cells, IgM and Protective Humoral Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $913,429 | September 23, 2019 | August 31, 2025 | BAUMGARTH, NICOLE | reporter.nih.gov |
| Mechanisms of age-specific differences in the Type I IFN response to respiratory viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $901,284 | September 8, 2020 | August 31, 2024 | CAREY, ALISON J | reporter.nih.gov |
| Endolysins as tools to eradicate pneumococcal biofilms and development of protective immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $901,010 | December 9, 2022 | November 30, 2023 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| Predictive Modeling of Influenza-Pneumococcal Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $885,870 | July 1, 2018 | June 30, 2024 | SMITH, AMBER M | reporter.nih.gov |
| Enhancing neutrophil function in neutropenia-related pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $885,000 | August 1, 2009 | April 30, 2024 | LUO, HONGBO R | reporter.nih.gov |
| Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $864,948 | July 3, 2023 | December 31, 2026 | DAVENPORT, GREGORY | reporter.nih.gov |
| Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $860,629 | June 21, 2022 | August 18, 2023 | RAO, GAURI G | reporter.nih.gov |
| Harnessing ZBP1-driven cell death to improve influenza vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $847,917 | August 13, 2021 | July 31, 2023 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Development of neonatal innate lung defenses is dependent on gastrointestinal commensal bacteria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $835,296 | September 1, 2018 | August 31, 2024 | DESHMUKH, HITESH | reporter.nih.gov |
| Harnessing ZBP1-triggered cell death to enhance influenza vaccine responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $833,534 | August 7, 2023 | July 31, 2024 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| New genetic models for C5a receptors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $825,000 | July 1, 2018 | June 30, 2024 | BOSMANN, MARKUS | reporter.nih.gov |
| Biology and infection of bats with novel bat influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $824,854 | January 10, 2018 | December 31, 2024 | MA, WENJUN | reporter.nih.gov |
| Novel adjuvant to boost humoral and cellular immune responses against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $820,609 | May 15, 2018 | April 30, 2025 | CHEN, XINYUAN | reporter.nih.gov |
| Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $813,514 | May 8, 2020 | April 30, 2023 | CRAIGO, JODI K | reporter.nih.gov |
| Impact of prior influenza exposures on antibody repertoires to new viral strains | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $807,244 | August 15, 2014 | July 31, 2024 | HENSLEY, SCOTT ERIC | reporter.nih.gov |
| Role of Microbiome in Neonatal Lung Maturation and Immune Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $799,909 | March 19, 2018 | February 29, 2024 | MILLER, LISA A | reporter.nih.gov |
| Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study | NIH | National Heart, Lung, and Blood Institute | 2021 | $793,344 | June 1, 2020 | May 31, 2022 | TREGGIARI, MIRIAM | reporter.nih.gov |
| Molecular Mechanism of Action of the Influenza PA-X Host Shutoff Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $788,424 | May 25, 2018 | April 30, 2024 | GAGLIA, MARTA MARIA | reporter.nih.gov |
| The Impact of Aging and HIV Infection on Immunologic and Transcriptomic Signatures of Influenza Vaccine Response | NIH | National Institute on Aging | 2021 | $779,116 | August 15, 2017 | April 30, 2023 | SHAW, ALBERT C | reporter.nih.gov |
| Inhibition of PAR2 as therapeutic approach to enhance anti-viral immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $777,500 | August 15, 2018 | June 30, 2024 | ANTONIAK, SILVIO | reporter.nih.gov |
| Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $773,720 | January 1, 2019 | December 31, 2023 | PAUST, SILKE | reporter.nih.gov |
| Unfolded protein response in Influenza virus infection and inflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,859 | January 15, 2019 | December 31, 2023 | ANATHY, VIKAS | reporter.nih.gov |
| Structure and functional dynamics of virus-host protein interactions | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $772,397 | September 20, 2018 | August 31, 2024 | CHO, JAE HYUN | reporter.nih.gov |
| The effects of influenza virus genomic heterogeneity on replication dynamics and the host response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $770,146 | September 21, 2018 | August 31, 2024 | BROOKE, CHRISTOPHER BYRON | reporter.nih.gov |
| Innate immunity and inflammatory response of macrophages to Legionella infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $765,106 | September 14, 2018 | August 31, 2024 | ABU KWAIK, YOUSEF A | reporter.nih.gov |
| Early Events in Protein Folding | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $759,805 | June 1, 1996 | July 31, 2024 | DYER, RICHARD BRIAN | reporter.nih.gov |
| The role of Bik in the replication and severity of influenza A virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $754,629 | January 1, 2021 | August 8, 2022 | MEBRATU, YOHANNES AFEWORK | reporter.nih.gov |
| Engineering a diagnostic platform for rapid breath-based respiratory pathogen identification and treatment monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $747,000 | July 1, 2019 | June 30, 2025 | CHAN, LESLIE | reporter.nih.gov |
| Randomized Trial of Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia - Prevent 2 Study | NIH | National Heart, Lung, and Blood Institute | 2022 | $743,776 | September 19, 2022 | May 31, 2026 | TREGGIARI, MIRIAM | reporter.nih.gov |
| Strain Dependent Structure and Function of the Influenza NS1 Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | November 16, 2017 | October 31, 2024 | PETIT, CHAD | reporter.nih.gov |
| The Roles of LPS-Binding Protein Vascular Peroxidase-1 in Innate Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $742,500 | January 4, 2019 | December 31, 2023 | CHENG, GUANGJIE | reporter.nih.gov |
| Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $740,465 | May 22, 2017 | April 30, 2023 | TRENT, MICHAEL STEPHEN | reporter.nih.gov |
| Combustion Generated Particulate Pollution Affects Infant Respiratory Health | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $735,130 | September 1, 2006 | August 31, 2024 | CORMIER, STEPHANIA A | reporter.nih.gov |
| Preclinical development of a synthetic lung surfactant dry powder aerosol for acute respiratory distress syndrome patients receiving different modes of ventilation support | NIH | National Heart, Lung, and Blood Institute | 2022 | $719,373 | September 22, 2022 | June 30, 2023 | LONGEST, P. WORTH | reporter.nih.gov |
| Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $704,782 | April 1, 2017 | March 31, 2024 | BOYD, SCOTT DEXTER | reporter.nih.gov |
| LOX-1 as a protective countermeasure in response to lung infection | NIH | National Heart, Lung, and Blood Institute | 2022 | $703,500 | September 19, 2022 | June 5, 2023 | QUINTON, LEE | reporter.nih.gov |
| Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $696,618 | August 10, 2018 | July 31, 2023 | LUNA, BRIAN MICHAEL | reporter.nih.gov |
| Nanovaccine-Mediated Immune Protection Against Influenza Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $680,912 | June 1, 2017 | May 31, 2023 | LEGGE, KEVIN L | reporter.nih.gov |
| Zinc intervention in prevention of pneumonia in elderly | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $679,500 | July 1, 2021 | June 30, 2024 | PANDA, ALEXANDER | reporter.nih.gov |
| Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $675,832 | February 1, 2017 | January 31, 2023 | ZAND, MARTIN S | reporter.nih.gov |
| Mechanisms of influenza transmission bottlenecks: impact on viral evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $659,143 | January 1, 2017 | December 31, 2023 | FRIEDRICH, THOMAS C. | reporter.nih.gov |
| Role of preexisting immunity on airborne transmission of influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $644,203 | February 22, 2022 | January 31, 2023 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| SARS-CoV-2 tropism in the brain and its relationship to COVID-19 pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 | $642,597 | September 25, 2021 | August 31, 2023 | YAKOUB, ABRAAM M. | reporter.nih.gov |
| New Nasal Spray Influenza Vaccine for Children (Research Supplement for Post Baccalaureate Diversity Candidate) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $625,772 | March 10, 2023 | February 28, 2026 | ZENG, MINGTAO | reporter.nih.gov |
| Repertoire studies of human antibodies to RSV and MPV F | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $621,866 | September 6, 2018 | August 31, 2023 | JARDETZKY, THEODORE S | reporter.nih.gov |
| Predictors of Influenza-Associated Absenteeism and Impact of Vaccination in a Cohort of Guatemalan Agricultural Workers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $619,202 | September 11, 2019 | August 31, 2024 | OLSON, DANIEL | reporter.nih.gov |
| Lung Macrophage Memory Development and Responses in Secondary Pneumonia and Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $610,868 | August 27, 2021 | July 31, 2025 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| Host control mechanisms against K. pneumoniae infection in the lungs | NIH | National Heart, Lung, and Blood Institute | 2021 | $603,934 | April 1, 2018 | March 31, 2024 | CHEN, KONG | reporter.nih.gov |
| Encephalitic viral infection and susceptibility to dopaminergic neurotoxins | NIH | National Institute of Environmental Health Sciences | 2021 | $603,534 | September 20, 2019 | August 31, 2024 | TJALKENS, RONALD | reporter.nih.gov |
| Arsenic and immune response to influenza vaccination in pregnant women and newborns | NIH | National Institute of Environmental Health Sciences | 2021 | $600,834 | March 1, 2017 | November 30, 2023 | HEANEY, CHRISTOPHER D | reporter.nih.gov |
| Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $600,000 | July 5, 2022 | July 5, 2024 | CLEMENTS, DAVID | reporter.nih.gov |
| Formulation of a prophylactic vaccine against Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,999 | March 16, 2022 | February 28, 2025 | NAGEL, AARON C | reporter.nih.gov |
| TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS. | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,980 | September 30, 2023 | September 29, 2025 | SINGLETON, KENTNER | reporter.nih.gov |
| DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,925 | September 30, 2023 | September 29, 2025 | ONHO, SAM | reporter.nih.gov |
| MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,806 | September 30, 2023 | September 29, 2025 | SINGLETON, KENTNER | reporter.nih.gov |
| Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $599,788 | August 11, 2022 | July 31, 2025 | GOMPERTS, EDWARD | reporter.nih.gov |
| DEVELOPMENT OF TOLL-LIKE RECEPTOR AGONISTS TO STRENGTHEN SUBLINGUAL VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $599,582 | January 10, 2022 | January 9, 2024 | FANGER, NEIL | reporter.nih.gov |
| Pn3Pase as an Effective Enzyme Therapeutic for Streptococcus Pneumoniae type 3 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $598,900 | July 9, 2021 | June 30, 2024 | AVCI, FIKRI Y | reporter.nih.gov |
| Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $598,124 | August 15, 2022 | June 30, 2024 | WROBEL, JAY EDWARD | reporter.nih.gov |
| APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS. | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $597,598 | January 10, 2022 | January 9, 2024 | ROTHSTEIN, SAM | reporter.nih.gov |
| Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $596,643 | August 18, 2022 | July 31, 2025 | KAZEMINY, ASSAD | reporter.nih.gov |
| Development of Coccidioides Cytokine Release Assay | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $596,247 | March 1, 2021 | February 28, 2023 | WHEAT, LAWRENCE JOSEPH | reporter.nih.gov |
| A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $593,112 | January 1, 2022 | December 31, 2024 | HARDING, CHRISTIAN | reporter.nih.gov |
| A Novel Broad-spectrum Antiviral Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $590,654 | January 1, 2021 | December 31, 2022 | MURAD, JOANA M | reporter.nih.gov |
| Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $583,152 | September 8, 2022 | August 31, 2025 | AKERLEY, BRIAN | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $582,371 | May 13, 2021 | April 30, 2023 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Endothelial antigen presentation to T cells as a pathogenic mechanism in influenza-induced acute lung injury. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $564,041 | March 15, 2021 | June 30, 2022 | ZHANG, LIANGHUI | reporter.nih.gov |
| Synthetic multi-component influenza vaccines to elicit broad immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $562,640 | August 13, 2021 | July 31, 2023 | BOONS, GEERT-JAN | reporter.nih.gov |
| Obesity dysregulates immune and metabolic status in asthma and alters infection susceptibility. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $560,844 | December 14, 2018 | November 30, 2023 | HENRICKSON, SARAH E | reporter.nih.gov |
| Biology of Influenza Virus Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $559,056 | June 8, 2019 | May 31, 2025 | ORTIGOZA, MILA BRUM | reporter.nih.gov |
| B-1 cells, IgM and Protective Humoral Immunity to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $553,449 | September 23, 2019 | August 31, 2022 | BAUMGARTH, NICOLE | reporter.nih.gov |
| Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,376 | February 10, 2017 | January 31, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Genetic Analysis of Legionella Phagosome Trafficking | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $544,169 | August 1, 2017 | July 31, 2023 | ROY, CRAIG R. | reporter.nih.gov |
| Macrophage differentiation and disease outcome in influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $542,926 | December 5, 2016 | November 30, 2023 | VOGEL, STEFANIE N. | reporter.nih.gov |
| Netosis in Trauma mediated Acute Lung Injury | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $540,344 | September 14, 2021 | July 31, 2024 | LEONARD, JENNIFER | reporter.nih.gov |
| Effect of Neonatal Hyperoxia on Alveolar Development and Infection | NIH | National Heart, Lung, and Blood Institute | 2021 | $536,581 | December 10, 2008 | August 31, 2023 | O'REILLY, MICHAEL A | reporter.nih.gov |
| Functional Implications of Tfh Cell Heterogeneity after Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $536,245 | August 20, 2021 | July 31, 2022 | BALLESTEROS-TATO, ANDRE | reporter.nih.gov |
| Consequences of Direct Viral-Bacterial Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $531,058 | July 20, 2021 | June 30, 2023 | ROSCH, JASON W. | reporter.nih.gov |
| IDENTIFICATION AND CHARACTERIZATION OF RNA STRUCTURES IN THE GENOME OF INFLUENZA VIRUS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $521,901 | July 13, 2018 | June 30, 2023 | BOON, ADRIANUS CM | reporter.nih.gov |
| A 3D human tissue-engineered lung model to study immune responses to Respiratory Syncytial Virus | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $517,917 | September 20, 2018 | June 30, 2024 | KOVATS, SUSAN | reporter.nih.gov |
| Impact of Early-in-life Disruption of Lung Development on Adult Lung Progenitor Function | NIH | National Heart, Lung, and Blood Institute | 2021 | $516,867 | September 1, 2018 | June 30, 2023 | SUN, XIN | reporter.nih.gov |
| ENaC-α mediates lung fluid clearance and capillary barrier function in pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 | $515,730 | July 1, 2018 | June 30, 2023 | LUCAS, RUDOLF | reporter.nih.gov |
| Alveolar macrophage-derived extracellular vesicles inhibit influenza infection in epithelial cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $508,680 | August 15, 2019 | September 9, 2023 | SCHNEIDER, DANIEL J | reporter.nih.gov |
| Inflammasomes: Regulation and Function in Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 | $508,492 | July 1, 1996 | March 31, 2023 | CHOI, MARY E | reporter.nih.gov |
| The Function and Potential Application of Extracellular Vesicle Derived Clara Cell Protein 16 in Gram-negative Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2023 | $501,482 | September 1, 2023 | August 31, 2025 | ZHANG, DUO | reporter.nih.gov |
| Quantifying the genetic and environmental factors driving avian influenza spillover | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $498,000 | September 1, 2022 | August 31, 2025 | MONCLA, LOUISE HILLIER | reporter.nih.gov |
| Lincenc1 regulates the lipopolysaccharide-induced inflammatory response in macrophages | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $495,100 | June 20, 2020 | May 31, 2024 | ZHANG, DUO | reporter.nih.gov |
| Mitochondrial metabolic regulation of lung epithelium: alveolar generation and regeneration | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $489,888 | September 17, 2019 | August 31, 2024 | HAN, SEUNGHYE | reporter.nih.gov |
| Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $487,290 | April 1, 2019 | February 29, 2024 | SALISBURY, MARGARET LOUISE | reporter.nih.gov |
| Identification of RNA-binding proteins in Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $486,750 | April 25, 2022 | March 31, 2025 | DOVE, SIMON L | reporter.nih.gov |
| Real-time predictive modeling for public health departments to control infectious diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $484,500 | August 1, 2022 | June 30, 2023 | LO, NATHAN | reporter.nih.gov |
| Alu dsRNAs as adjuvants for influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $481,990 | April 7, 2022 | March 31, 2025 | AUNE, THOMAS M. | reporter.nih.gov |
| Pulmonary Epithelial Dynamics and Innate Host Defense | NIH | National Heart, Lung, and Blood Institute | 2021 | $480,973 | December 7, 2017 | November 30, 2022 | MCCORMACK, FRANCIS XAVIER | reporter.nih.gov |
| Metformin to improve immunological health and vaccine responses | NIH | National Institute on Aging | 2021 to 2023 | $478,119 | May 1, 2020 | February 28, 2025 | LEE, GRACE CHOI | reporter.nih.gov |
| Impact of Pandemic Mitigation Efforts on Colonization and Transmission of Respiratory Pathogens and Antibiotic Resistance Genes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $475,750 | June 8, 2022 | May 31, 2024 | HOWARD, LEIGH MEREDITH | reporter.nih.gov |
| Nasal RNA response to respiratory viral infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $472,750 | April 1, 2022 | March 31, 2024 | PAN, TAO | reporter.nih.gov |
| ILC2-Mediated Protection from Acute Lung Infection | NIH | National Heart, Lung, and Blood Institute | 2021 | $469,445 | December 12, 2017 | November 30, 2022 | METZGER, DENNIS W | reporter.nih.gov |
| Features of PMN Senescence that Lead to Susceptibility to Pneumococcal Infection | NIH | National Institute on Aging | 2021 to 2022 | $469,115 | March 1, 2021 | February 29, 2024 | MECSAS, JOAN C | reporter.nih.gov |
| Characterization of assembly factors for type IV secretion systems | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $466,999 | June 21, 2021 | May 31, 2024 | CAPARON, MICHAEL G. | reporter.nih.gov |
| Dynactin 4 regulation of lung injury | NIH | National Heart, Lung, and Blood Institute | 2021 | $466,844 | January 1, 2018 | November 30, 2022 | CHEN, PETER | reporter.nih.gov |
| Antibiotic resistance among hypermutator carbapenem resistant Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $466,199 | June 21, 2022 | May 31, 2025 | NGUYEN, M. HONG THI | reporter.nih.gov |
| Autosomal dominant OTULIN deficiency and staphylococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $466,125 | August 15, 2022 | July 31, 2024 | BOISSON, BERTRAND | reporter.nih.gov |
| Regulation of Follicular T cell Responses in the Lung by Ion Channels | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $465,462 | September 25, 2017 | August 31, 2023 | FESKE, STEFAN | reporter.nih.gov |
| Role of a novel human-virus chimeric protein generated by upstream translation and genetic overprinting | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $464,875 | November 1, 2021 | October 31, 2023 | MARAZZI, IVAN | reporter.nih.gov |
| The Role of TRIM6 and Ubiquitin in Influenza Virus-Induced Pathology | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $461,016 | May 13, 2021 | April 30, 2022 | RAJSBAUM, RICARDO | reporter.nih.gov |
| Risk Stratification and Decision Support to Improve Care and Outcomes in Children with Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $460,844 | February 7, 2017 | January 31, 2023 | WILLIAMS, DEREK J. | reporter.nih.gov |
| Host response-based screening for unexpected or emerging respiratory viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $460,625 | March 15, 2021 | February 28, 2023 | FOXMAN, ELLEN FLESCHER | reporter.nih.gov |
| Age-Associated B Cells Specialized for Immunity to Pathogens? | NIH | National Institute on Aging | 2021 to 2022 | $460,625 | May 15, 2021 | January 31, 2023 | SWAIN, SUSAN L | reporter.nih.gov |
| The impact of senescence on immune memory | NIH | National Institute on Aging | 2023 | $453,163 | September 15, 2023 | September 14, 2025 | HAYNES, LAURA | reporter.nih.gov |
| Can Senolytics Improve the Aged Response to Viral Infection | NIH | National Institute on Aging | 2021 to 2022 | $451,000 | September 1, 2021 | May 31, 2024 | HAYNES, LAURA | reporter.nih.gov |
| mRNA vaccine responses in PLWH | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $450,313 | August 22, 2022 | July 31, 2024 | BLANKSON, JOEL N | reporter.nih.gov |
| Environmental arsenic, immunoregulation, and viral disease risk | NIH | National Institute of Environmental Health Sciences | 2022 to 2023 | $450,288 | March 11, 2022 | August 31, 2024 | COFFMAN, JAMES A | reporter.nih.gov |
| Deciphering the impact of sedative choice on the dynamics of Klebsiella pneumoniae lung infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $449,200 | November 16, 2021 | October 31, 2023 | FREITAG, NANCY ELIZABETH | reporter.nih.gov |
| Role of ATII cell senescence in influenza pathogenesis in aging | NIH | National Institute on Aging | 2023 | $448,270 | September 1, 2023 | August 31, 2025 | DAVIS, IAN CHRISTOPHER | reporter.nih.gov |
| Siderophores of Legionella pneumophila | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $447,861 | July 23, 2018 | June 30, 2023 | CIANCIOTTO, NICHOLAS P | reporter.nih.gov |
| A revised model for immune imprinting by influenza virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $447,212 | June 1, 2022 | May 31, 2026 | SANT, ANDREA JANINE | reporter.nih.gov |
| RBC-mediated mopping of cytokines for the treatment of pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $446,875 | September 24, 2021 | August 31, 2023 | BRENNER, JACOB | reporter.nih.gov |
| TNF and caspase-8-mediated control of Legionella pneumophila infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $446,667 | March 5, 2021 | February 29, 2024 | SHIN, SUNNY | reporter.nih.gov |
| Identifying niche specific adaptations in Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $445,587 | March 24, 2022 | February 28, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Tuft Cells Modulate Macrophage Response Following Lung Viral Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $445,500 | February 1, 2022 | January 31, 2025 | QUE, JIANWEN | reporter.nih.gov |
| A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $444,989 | February 1, 2022 | July 31, 2024 | ARNABOLDI, PAUL MICHAEL | reporter.nih.gov |
| Mechanism of membrane inactivation method to prepare enveloped virus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $444,397 | June 23, 2021 | May 31, 2024 | AGUILAR-CARRENO, HECTOR | reporter.nih.gov |
| Dissecting ADP-ribosylation as an innate immune response countering influenza virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $443,476 | September 22, 2021 | August 31, 2024 | MEHLE, ANDREW | reporter.nih.gov |
| Sex-Dependent Regulation of Host Factors Influencing SARS-CoV-2 Infection and COVID-19 Disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $442,751 | April 15, 2022 | March 31, 2024 | ANGUERA, MONTSERRAT C | reporter.nih.gov |
| HEMOGLOBIN-INDUCED VIRULENCE IN STREPTOCOCCUSPNEUMONIAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $441,005 | March 10, 2021 | February 29, 2024 | VIDAL, JORGE EUGENIO | reporter.nih.gov |
| Novel small-molecule inhibitors of SARS-CoV-2 protease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $440,000 | December 1, 2020 | November 30, 2023 | SONG, YONGCHENG | reporter.nih.gov |
| Microglia mediate cognitive dysfunction in elderly survivors of pneumonia | NIH | National Institute on Aging | 2022 | $440,000 | February 1, 2022 | January 31, 2025 | MISHARIN, ALEXANDER | reporter.nih.gov |
| Microbial and Host Factors that Promote Epithelial Disruption and S. pneumoniae Transit out of the Lung | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $439,500 | April 1, 2021 | March 31, 2025 | ADAMS, WALTER ISAIAH | reporter.nih.gov |
| Rational identification of Corynebacterium strains for use as probiotics | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $439,416 | May 16, 2022 | April 30, 2025 | SEED, PATRICK C. | reporter.nih.gov |
| Development of a Novel rAAV Vector Without Cross-species Barrier to Transduce Human and Ferret Conducting Airways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $438,238 | June 15, 2021 | May 31, 2024 | QIU, JIANMING | reporter.nih.gov |
| Function of the Klebsiella pneumoniae RND efflux systems | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $436,990 | June 17, 2022 | May 31, 2025 | BINA, JAMES EDWARD | reporter.nih.gov |
| Tetrahydrothieno[2,3-c]pyridines as Vaccine Co-adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $434,000 | November 25, 2020 | October 31, 2022 | SHUKLA, NIKUNJ | reporter.nih.gov |
| Examining the Dynamic Architecture of the Influenza Virus Genome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $433,813 | June 1, 2021 | May 31, 2024 | LEE, NARA | reporter.nih.gov |
| Investigating virus-host interactions with prime editing and genetic code expansion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $433,125 | May 21, 2021 | April 30, 2024 | VAHEY, MICHAEL D | reporter.nih.gov |
| High-density flagellin-displayed virus-like particle for universal influenza vaccine development' | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $433,125 | June 11, 2021 | May 31, 2024 | CHEN, XINYUAN | reporter.nih.gov |
| Negative regulation of inflammation during Klebsiella pneumoniae infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $432,980 | May 11, 2021 | April 30, 2024 | TREVEJO-NUNEZ, GIRALDINA | reporter.nih.gov |
| Quantifying the spectrum and dynamics of B-cell binding avidity in response to influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,750 | February 1, 2021 | January 31, 2024 | GEORGE, STEVEN CARL | reporter.nih.gov |
| Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,417 | November 24, 2020 | October 31, 2024 | SHIELDS, RYAN K | reporter.nih.gov |
| To employ gamma-peptide nucleic acid oligomers to interfere with viral replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,241 | April 2, 2021 | March 31, 2023 | LEE, NARA | reporter.nih.gov |
| Human Genetic Variation Regulating Transcriptional Response and Cellular Susceptibility to Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $430,984 | March 9, 2021 | February 28, 2023 | KO, DENNIS CHUN-YONE | reporter.nih.gov |
| Role of RNA helicase DDX1 in influenza A virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $430,721 | August 17, 2022 | July 31, 2025 | DU, YUCHUN | reporter.nih.gov |
| F-18 fluorodeoxysorbitol for detecting response of bacterial infection to treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,500 | March 16, 2021 | February 29, 2024 | NG, CHIN K | reporter.nih.gov |
| Susceptibility determinants to Legionella pneumophila infection in smokers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,000 | March 18, 2021 | August 31, 2023 | AMER, AMAL O | reporter.nih.gov |
| Exploring protein translocation by the Legionella pneumophila Dot/Icm Type IV Section System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $429,000 | June 11, 2021 | May 31, 2024 | OHI, MELANIE DIANE | reporter.nih.gov |
| Synergistic Interactions of SARs-CoV2 and environmental toxicants in Experimental Parkinsonism | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $429,000 | July 1, 2021 | December 31, 2022 | SMEYNE, RICHARD J | reporter.nih.gov |
| Small RNA based control of zinc homeostasis in Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $429,000 | May 20, 2022 | April 30, 2024 | DE LAY, NICHOLAS R. | reporter.nih.gov |
| Investigation of capsule interactions that promote antimicrobial peptide activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $428,855 | March 19, 2021 | February 29, 2024 | DAVIES, BRYAN WILLIAM | reporter.nih.gov |
| Metabolomic Prediction of Pneumonia Severity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $427,625 | April 21, 2021 | March 31, 2024 | AMBROGGIO, LILLIAM | reporter.nih.gov |
| Sex-specific Immune Responses to Severe Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $427,008 | December 1, 2020 | November 30, 2023 | SHOEMAKER, JASON EDWARD | reporter.nih.gov |
| Resolution of Diffuse Inflammatory Lung Injury in Neonatal Mice | NIH | National Heart, Lung, and Blood Institute | 2021 | $426,425 | June 15, 2013 | August 31, 2023 | MCGRATH-MORROW, SHARON ANN | reporter.nih.gov |
| Animal models of SARS-CoV-2 bacterial Coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | May 16, 2022 | April 30, 2025 | XIANG, YAN | reporter.nih.gov |
| Biology of hypervirulent Klebsiella pneumoniae translocation from the gastrointestinal tract | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | November 1, 2021 | October 31, 2024 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| The impact of aging and thymus regeneration on tissue-resident CD8 T cell responses to viral lung infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $426,250 | June 1, 2022 | May 31, 2025 | GRIFFITH, ANN VENABLES | reporter.nih.gov |
| Mechanisms underlying adhesion and colonization in pneumococcal keratitis | NIH | National Eye Institute | 2023 | $426,250 | August 1, 2023 | July 31, 2025 | MARQUART, MARY E | reporter.nih.gov |
| Development of broadly-protective vaccines for influenza B viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,718 | February 25, 2021 | June 30, 2023 | KAWAOKA, YOSHIHIRO | reporter.nih.gov |
| Impact of Dual Alcohol and Cannabis Use on Lung | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $423,961 | August 20, 2021 | July 31, 2024 | BURNHAM, ELLEN L | reporter.nih.gov |
| Small viral RNAs as determinants of influenza A virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $423,750 | February 4, 2020 | September 6, 2021 | TENOEVER, BENJAMIN R. | reporter.nih.gov |
| Impact of Heightened ER Stress on NLRP3 Activation in Aged Lung during Infection | NIH | National Institute on Aging | 2021 | $423,750 | September 1, 2017 | May 31, 2023 | STOUT DELGADO, HEATHER WINONA | reporter.nih.gov |
| Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $423,750 | April 15, 2010 | February 28, 2023 | BHARDWAJ, NINA | reporter.nih.gov |
| Targeting macrophages to reduce the combined injury effects of radiation and virus exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $423,500 | May 5, 2022 | April 30, 2024 | MARPLES, BRIAN | reporter.nih.gov |
| Macrophage Redox State in Sterilizing and Injurious Inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $418,223 | April 7, 2017 | March 31, 2023 | BONINI, MARCELO G. | reporter.nih.gov |
| Mathematical Modeling of Influenza Severity in Outbred Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $418,042 | November 25, 2020 | October 31, 2023 | ALCORN, JOHN F | reporter.nih.gov |
| Role of OCIAD1 in RIG-I-mediated STAT1 signaling pathway | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $418,000 | January 24, 2022 | December 31, 2024 | LI, SHITAO | reporter.nih.gov |
| Antibody therapy for pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $417,500 | November 10, 2016 | October 31, 2022 | PIROFSKI, LIISE-ANNE | reporter.nih.gov |
| Integrated modeling of Klebsiella pneumoniae infections based on bacterial genotype, patient factors and colonization status | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $417,192 | February 15, 2017 | January 31, 2023 | BACHMAN, MICHAEL ABBOTT | reporter.nih.gov |
| C3 Mitigates Epithelial Injury in Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $416,942 | September 1, 2019 | August 31, 2025 | KULKARNI, HRISHIKESH SATISH | reporter.nih.gov |
| Pathogenesis of myalgia and fatigue after SARS-CoV-2 infection | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $416,626 | September 23, 2022 | August 31, 2024 | HOMMA, SACHIKO | reporter.nih.gov |
| Impaired NK cell function by the synthetic food additive tBHQ | NIH | National Institute of Environmental Health Sciences | 2022 to 2023 | $414,803 | September 6, 2022 | August 31, 2024 | ROCKWELL, CHERYL ELIZABETH | reporter.nih.gov |
| Mimicking evolution to define mechanisms of airborne transmission of H7N9 viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $412,346 | September 2, 2021 | August 31, 2024 | SUTTON, TROY CLAVELL | reporter.nih.gov |
| Coupling Machine Learning with Agent-Based Modeling to Design a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $411,905 | May 9, 2022 | April 30, 2025 | SPRENGER, KAYLA | reporter.nih.gov |
| Lnc-PINK regulation of innate immunity in lung epithelial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $411,400 | March 5, 2021 | February 28, 2025 | LIU, LIN | reporter.nih.gov |
| Neuroendocrine control of TLR4-dependent inflammation in influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $411,250 | May 1, 2021 | April 30, 2024 | SHIREY, KARI ANN | reporter.nih.gov |
| Optimizing functional synergies between local and systemic memory CD4 T cell responses to influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $410,808 | December 10, 2020 | November 30, 2023 | MCKINSTRY, KARL KAI | reporter.nih.gov |
| Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases" | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $406,756 | April 2, 2020 | December 31, 2022 | JIA, HONGPENG | reporter.nih.gov |
| Upper-respiratory infection, oligodendrocyte plasticity and behavior | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $405,672 | September 1, 2021 | February 28, 2025 | STEELMAN, ANDREW JONATHAN | reporter.nih.gov |
| Strategies to Enhance Pneumonia Care via Intermediate Intensive Care (STEP IN) | NIH | National Heart, Lung, and Blood Institute | 2021 | $403,484 | September 1, 2017 | May 31, 2022 | COOKE, COLIN | reporter.nih.gov |
| The vital role of T404 phosphorylation of STAT2 in post-viral bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 | $402,500 | September 1, 2022 | August 31, 2024 | WANG, YUXIN | reporter.nih.gov |
| REGULATION OF HOST RESPONSES TO RESPIRATORY VIRAL INFECTION BY ISG15 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $393,750 | August 1, 2009 | May 31, 2023 | LENSCHOW, DEBORAH J | reporter.nih.gov |
| Storage and recall of human B cell memory of influenza over tissues and time | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $392,800 | January 13, 2017 | December 31, 2023 | BOYD, SCOTT DEXTER | reporter.nih.gov |
| Bacteriophage-mediated microbiota modification to prevent colorectal cancer development | NIH | National Cancer Institute | 2022 to 2023 | $387,838 | May 10, 2022 | February 28, 2025 | EL HADDAD, LYNN | reporter.nih.gov |
| Electronic Cigarette Vapor Inhalation Adversely Affects Lung Cellular and Physiologic Function and Alters Systemic Inflammatory Pathways | NIH | National Heart, Lung, and Blood Institute | 2021 | $387,500 | April 1, 2017 | December 31, 2022 | CROTTY ALEXANDER, LAURA ELISE | reporter.nih.gov |
| Mechanisms and consequences of epithelial cell survival from influenza virus infection. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $385,000 | June 1, 2017 | May 31, 2023 | LANGLOIS, RYAN | reporter.nih.gov |
| Influenza virus host shutoff mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $385,000 | September 25, 2017 | August 31, 2023 | TAKIMOTO, TORU | reporter.nih.gov |
| Novel antimicrobials to combat Gram-negative bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $383,750 | August 16, 2023 | July 31, 2025 | WANG, GUANGSHUN | reporter.nih.gov |
| Visualization of Influenza Viral RNA Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $381,870 | August 16, 2018 | July 31, 2022 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| Visualization of Influenza Viral RNA Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $381,589 | August 11, 2022 | July 31, 2024 | LAKDAWALA, SEEMA S. | reporter.nih.gov |
| Eosinophils as Regulators of Host Immunity against Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $380,000 | March 6, 2017 | August 31, 2022 | SAMARASINGHE, AMALI | reporter.nih.gov |
| Regulation of phosphodiesterases and cAMP signaling during the host-pathogen interaction in the pulmonary endothelium | NIH | National Heart, Lung, and Blood Institute | 2021 | $378,245 | April 1, 2018 | March 31, 2023 | RICHTER, WITO H | reporter.nih.gov |
| Molecular and cellular mechanism regulating innate immunity and inflammation during pattern recognition receptor activation and respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $375,233 | June 1, 2010 | July 31, 2024 | BOSE, SANTANU | reporter.nih.gov |
| Midcareer Award in Translational Immunology of Aging | NIH | National Institute on Aging | 2021 to 2022 | $375,192 | August 1, 2012 | April 30, 2023 | SHAW, ALBERT C | reporter.nih.gov |
| Development of LspA Inhibitors to Treat Gram-negative Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $374,000 | July 1, 2022 | June 30, 2024 | SUTTERLIN, HOLLY ANN | reporter.nih.gov |
| The role of circadian clock proteins in innate and adaptive immunity | NIH | National Institute of General Medical Sciences | 2022 | $373,588 | September 26, 2022 | June 30, 2023 | ROSENGART, MATTHEW RANDALL | reporter.nih.gov |
| Molecular Mechanism of Lung Barrier Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 | $371,250 | July 1, 2018 | May 31, 2024 | DING, QIANG | reporter.nih.gov |
| ALTERING THE IMMUNE LANDSCAPE TO AUGMENT BONE REGENERATION | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $369,050 | September 1, 2023 | August 31, 2025 | ALGE, DANIEL | reporter.nih.gov |
| Pneumococcal dynamics in the conjugate vaccine era: Addressing unanswered questions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $368,213 | January 17, 2019 | December 31, 2023 | HOWARD, LEIGH MEREDITH | reporter.nih.gov |
| Development and implementation of a pediatric AI multi-modal digital stethoscope and respiratory surveillance system in South Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $367,680 | August 7, 2023 | July 31, 2025 | MCCOLLUM, ERIC DOUGLASS | reporter.nih.gov |
| Host Response and Immunity to Yersenia pestis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $365,222 | May 8, 2017 | April 30, 2023 | ANDERSON, DEBORAH M | reporter.nih.gov |
| Pathogenic role of IL-17 response in Streptococcus pneumoniae nasopharyngeal pathogenesis during an influenza virus co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $357,081 | December 3, 2019 | November 30, 2024 | KHAN, NADEEM | reporter.nih.gov |
| Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia (P-RAPP) | NIH | National Heart, Lung, and Blood Institute | 2021 | $353,127 | September 1, 2020 | June 30, 2022 | FLORIN, TODD ADAM | reporter.nih.gov |
| INTESTINAL MICROBIAL REGULATION OF ANTIVIRAL IMMUNITY | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $351,212 | December 7, 2017 | November 30, 2022 | STEED, ASHLEY | reporter.nih.gov |
| Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung InnateDefenses in the Fetus and Newborn Infant | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $348,400 | July 17, 2019 | June 30, 2023 | PRINCE, LAWRENCE S | reporter.nih.gov |
| The Effect of Maternal Cells on Infant Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $341,450 | December 12, 2017 | July 31, 2023 | HARRINGTON, WHITNEY ELIZABETH | reporter.nih.gov |
| Preventing avoidable deaths from pneumonia by improving use of intensive care | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $334,708 | August 7, 2018 | September 30, 2023 | VALLEY, THOMAS SEBASTIAN | reporter.nih.gov |
| Influenza nucleoprotein interactions | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $330,750 | February 8, 2012 | December 31, 2024 | NEWCOMB, LAURA LYNN | reporter.nih.gov |
| Using Legionella-amoeba co-evolution to reveal new modes of immunity and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $330,434 | July 1, 2020 | June 30, 2022 | LEVIN, TERA CATHERINE | reporter.nih.gov |
| Regulation and function of immune suppressive T cells in aging | NIH | National Institute on Aging | 2021 | $325,950 | September 1, 2021 | August 31, 2023 | CHOUGNET, CLAIRE A. | reporter.nih.gov |
| Role of increased circulating microparticles in adverse outcomes of COVID-19 patients with diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $324,720 | April 1, 2022 | March 31, 2024 | HE, PINGNIAN | reporter.nih.gov |
| Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $323,786 | January 22, 2018 | December 31, 2022 | KITSIOS, GEORGIOS | reporter.nih.gov |
| Endothelial cell signaling in regeneration of the lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $323,380 | September 1, 2022 | December 31, 2023 | NIETHAMER, TERREN KATHRYN | reporter.nih.gov |
| Stress and the Genome: Testing the Impact of Social Effects on Gene Regulation | NIH | National Institute on Aging | 2021 | $320,763 | September 15, 2017 | March 31, 2024 | TUNG, JENNY | reporter.nih.gov |
| Distinct Function and Control of Regulatory T Cell Subsets During Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $318,416 | June 15, 2017 | March 31, 2023 | GRIFFITH, JASON W. | reporter.nih.gov |
| Simulation of Proton Translocation in Biomolecules | NIH | National Institute of General Medical Sciences | 2021 | $310,328 | May 1, 1996 | May 31, 2024 | VOTH, GREGORY A. | reporter.nih.gov |
| Pulsed Focused Ultrasound (pFUS) exposures and devices for tissue permeabilization without contrast agents | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $306,746 | January 19, 2021 | September 18, 2021 | KHOKHLOVA, TATIANA | reporter.nih.gov |
| Nasopharyngeal Microbiome and Risk of Bacterial Pathogen Colonization in Infants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $305,810 | May 23, 2018 | April 30, 2023 | KELLY, MATTHEW SCOTT | reporter.nih.gov |
| Respiratory infections and vaccination behaviors in patients with chronic inflammatory skin diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $305,095 | July 1, 2019 | June 30, 2024 | NOE, MEGAN H | reporter.nih.gov |
| Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis | NIH | National Eye Institute | 2022 | $300,156 | July 1, 2022 | June 30, 2023 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 1, 2020 | May 31, 2024 | OPPERMAN, TIMOTHY J. | reporter.nih.gov |
| Small molecule inhibitors of influenza virus nucleoprotein | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | May 12, 2021 | April 30, 2024 | ENGEL, DANIEL A | reporter.nih.gov |
| The First LANCL2-based therapeutic for influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | June 11, 2021 | December 10, 2022 | HONTECILLAS, RAQUEL | reporter.nih.gov |
| Treatment of Inflammatory Complications of Viral Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | June 20, 2022 | August 6, 2023 | AGRAWAL, ANDY | reporter.nih.gov |
| A comprehensive next generation sequencing diagnostic tool for lung infection among hospitalized patients | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | August 11, 2022 | July 31, 2024 | FINGERLIN, TASHA E. | reporter.nih.gov |
| Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | December 5, 2022 | November 30, 2024 | WU, REEN | reporter.nih.gov |
| Self-organizing synthetic human lungs on microchips to fight infection by RSV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | May 22, 2023 | April 30, 2024 | ETOC, FRED | reporter.nih.gov |
| Modular Sample Preparation for In-Field Viral Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $299,326 | September 15, 2023 | September 14, 2024 | SHARMA, ANJA | reporter.nih.gov |
| Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,218 | July 5, 2020 | June 30, 2022 | MACLEOD, DAVID A | reporter.nih.gov |
| Flu Vaccine Production Using a Novel Pandemic Response and Prevention Manufacturing Method | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $298,891 | May 1, 2023 | April 30, 2025 | ARTINGER, MICHAEL | reporter.nih.gov |
| Niclosamide Formulations for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,479 | July 8, 2022 | June 30, 2023 | FUJII, GARY | reporter.nih.gov |
| Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $297,412 | May 10, 2022 | April 30, 2025 | ERASMUS, JESSE HONG-SAE | reporter.nih.gov |
| Large scale in vitro production of capped polyadenylated mRNA-based vaccines in solid phase using immobilized enzymes | NIH | National Center for Advancing Translational Sciences | 2021 | $297,193 | September 23, 2021 | September 22, 2023 | KIREEVA, MARIA | reporter.nih.gov |
| Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $293,999 | February 10, 2020 | June 14, 2022 | SPELLBERG, BRAD J | reporter.nih.gov |
| BE IMMUNE: Behavioral Economics to Improve and Motivate vaccination Using Nudges through the EHR | NIH | National Institute on Aging | 2021 | $288,540 | August 15, 2020 | July 31, 2022 | MEHTA, SHIVAN JATIN | reporter.nih.gov |
| Very rapid, low cost multiplexed test for SARS, Influenza A and Influenza B Resubmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $285,597 | April 15, 2022 | March 31, 2024 | FARIS, GREGORY W | reporter.nih.gov |
| Rapid response to pandemic influenza via multi-antigen RNA-based vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $284,906 | February 10, 2022 | October 31, 2022 | MANDL, CHRISTIAN W. | reporter.nih.gov |
| Development of novel protein-based vaccine formulations to prevent pneumococcal colonization and disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $283,588 | September 17, 2020 | August 31, 2024 | GONZALEZ-JUARBE, NORBERTO | reporter.nih.gov |
| In Vivo Cluster AI Prediction (CLAIRE) of COVID-19 Disease Progression | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $278,889 | December 9, 2021 | July 31, 2022 | BUENDIA, PATRICIA | reporter.nih.gov |
| Development of an improved intranasal vaccine against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $275,107 | August 1, 2022 | July 31, 2024 | AMANNA, IAN JAMES | reporter.nih.gov |
| Lung epithelial cell reprogramming by CD4 T cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $270,692 | January 1, 2022 | March 31, 2023 | SHENOY, ANUKUL T | reporter.nih.gov |
| Functional Genetic Analysis of Klebsiella pneumoniae Hypervirulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $268,720 | July 15, 2021 | August 31, 2023 | MIKE, LAURA ANZALDI | reporter.nih.gov |
| Mechanisms of Interferon-Lambda Programming at the Innate-Adaptive Immune Interface for Protection Against Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $267,887 | March 9, 2021 | August 31, 2023 | HEMANN, EMILY ANN | reporter.nih.gov |
| Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $266,860 | July 1, 2023 | June 30, 2025 | AMBROGGIO, LILLIAM | reporter.nih.gov |
| T cell signal transduction in the regulation of T cell memory in response to infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $260,000 | May 1, 2015 | May 31, 2023 | TEIXEIRO, EMMA | reporter.nih.gov |
| Novel Peptide Immunomodulators for Treating Sepsis | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $259,121 | May 3, 2023 | April 30, 2026 | AHMAD, SAIRA | reporter.nih.gov |
| Improving influenza vaccines through wastewater-based macro-scale strain surveillance | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $256,575 | February 1, 2022 | July 31, 2022 | KANE, SARAH JO | reporter.nih.gov |
| New BioCascade System for Investigating the Airborne Transmission Modes of Respiratory Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $256,005 | January 26, 2021 | December 31, 2022 | EIGUREN FERNANDEZ, ARANTZAZU | reporter.nih.gov |
| Transient Gene Therapy as Broad Spectrum Antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $255,932 | September 1, 2021 | September 30, 2022 | BOGUNOVIC, DUSAN | reporter.nih.gov |
| RADX-TECH- SUPPORT SERVICES NEEDED FOR WORK PACKAGE 1 | NIH | National Heart, Lung, and Blood Institute | 2021 | $250,000 | January 19, 2021 | January 18, 2022 | PAIS, ANDREA | reporter.nih.gov |
| Developing a PIV5-based human metapneumovirus (HMPV) vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $249,999 | May 5, 2023 | October 31, 2024 | GINGERICH, MARIA CRISTINA | reporter.nih.gov |
| Investigating the development and clonal dynamics of broadly neutralizing B cells against influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $248,999 | August 8, 2022 | July 31, 2023 | GUTHMILLER, JENNA | reporter.nih.gov |
| Mechanisms by Which Alcohol-Induced Dysbiosis Impairs Host Defense Against Klebsiella Pneumoniae | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $246,208 | September 20, 2019 | August 31, 2023 | SAMUELSON, DERRICK R | reporter.nih.gov |
| Understanding the immunometabolic response to Klebsiella pneumonia infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $244,302 | April 1, 2022 | March 31, 2024 | WONG FOK LUNG, TANIA | reporter.nih.gov |
| A Point-of-Care Test for Rapid Diagnosis of Valley Fever | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $243,118 | July 24, 2023 | June 30, 2025 | GRILL, FRANCISCA | reporter.nih.gov |
| MECHANISTIC UNDERSTANDING OF INFLUENZA-HOST INTERACTIONS FROM A ZOONOTIC PERSPECTIVE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $242,774 | August 21, 2019 | August 31, 2022 | WU, NICHOLAS C. | reporter.nih.gov |
| Effect of Maternal Influenza Vaccination during Pregnancy on Risk of Infant Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $237,196 | May 21, 2018 | April 30, 2023 | ZERBO, OUSSENY | reporter.nih.gov |
| Identification of new or unrecognized virulence genes in hypervirulent Klebsiella pneumoniae and antivirulence genes in classical K. pneumoniae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $235,744 | August 19, 2020 | July 31, 2024 | RUSSO, THOMAS A | reporter.nih.gov |
| Determine the minimal level of replication required for broad protective immunity of influenza vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $234,000 | January 10, 2020 | December 31, 2021 | SHI, YUAN | reporter.nih.gov |
| Universal epitopes-based recombinant influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $233,688 | February 1, 2020 | January 31, 2023 | KANG, SANG-MOO | reporter.nih.gov |
| Determining how the giant Streptococcus Pneumoniae IgA1 protease cleaves its host IgA1 substrate and how this interaction can be blocked | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $233,250 | December 19, 2019 | November 30, 2022 | EISENMESSER, ELAN Z | reporter.nih.gov |
| Crosstalk between FceRI and MAVS signaling pathways in mast cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $228,750 | May 22, 2020 | April 30, 2022 | KAWAKAMI, TOSHIAKI | reporter.nih.gov |
| A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $227,250 | July 12, 2021 | June 30, 2022 | PICKING, WENDY L. | reporter.nih.gov |
| Oxidative killing of Pneumococcus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $226,500 | March 1, 2020 | February 28, 2023 | RADA, BALAZS | reporter.nih.gov |
| Development of SupraGuard ETT, A Next Generation Composite Endotracheal Tube for the Prevention of Ventilator-Associated Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 | $225,135 | September 15, 2021 | July 31, 2023 | VACHON, DAVID JOHN | reporter.nih.gov |
| Characterization of pneumococcal secretion chaperones required for virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $224,638 | January 1, 2020 | December 31, 2022 | CAHOON, LATY ADRIELLA | reporter.nih.gov |
| Establishing a relevant mouse model with susceptibility to non-adapted influenza viruses for vaccine challenge studies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $223,680 | July 6, 2020 | June 30, 2023 | YOUNT, JACOB | reporter.nih.gov |
| Assessing Flu-specific Humoral Immunity in Human Lung after Ex Vivo Lung Perfusion | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $222,750 | February 1, 2020 | January 31, 2023 | NELLORE, ANOMA | reporter.nih.gov |
| Capsule protects intracellular pneumococci during vascular endothelial cell translocation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $222,750 | March 1, 2020 | February 28, 2023 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Genetically engineered macrophages to treat pulmonary infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $216,942 | February 6, 2020 | January 31, 2024 | WEST, TIMOTHY EOIN | reporter.nih.gov |
| Establishing Mechanisms of LOX-1-Dependent Immune Regulation During Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $212,754 | August 1, 2022 | July 16, 2024 | KORKMAZ, FILIZ | reporter.nih.gov |
| Hospital-Associated Respiratory Virus Infections: Molecular Epidemiology, Clinical Outcomes, and Cost-Effectiveness of Interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $212,424 | January 2, 2019 | December 31, 2023 | PETRIE, JOSHUA GLENN | reporter.nih.gov |
| Investigating the relationship between antibiotics and nosocomial pneumonia. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | January 1, 2020 | December 31, 2022 | TORRES, VICTOR J. | reporter.nih.gov |
| Targeting Pneumococcal Colonization | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | March 1, 2020 | February 28, 2023 | WEISER, JEFFREY NEAL | reporter.nih.gov |
| Determining the induction of hemagglutinin stalk and neuraminidase antibody responses after LAIV vaccination in children | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | March 5, 2020 | February 28, 2022 | KRAMMER, FLORIAN | reporter.nih.gov |
| Multi-scale analysis of single cell sequencing data to dissect the complexity of influenza infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | July 10, 2020 | June 30, 2023 | FORST, CHRISTIAN | reporter.nih.gov |
| Utilization of the adjuvant effect of CRM197 protein to develop a trivalentprotein-vaccine against Streptococcus pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,500 | March 15, 2021 | February 28, 2022 | KHAN, NADEEM | reporter.nih.gov |
| Delineating the non-conventional MHC class I and class II peptidome of influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $209,990 | June 1, 2020 | May 31, 2022 | EISENLOHR, LAURENCE CRANE | reporter.nih.gov |
| Investigating the cellular responses to influenza virus infection and the origins of first exposure immune imprinting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $209,964 | September 1, 2021 | August 31, 2024 | METTELMAN, ROBERT C | reporter.nih.gov |
| Impact of TcR Signal Strength at the Effector Checkpoint on Protective CD4 T Cell Immunity to Influenza Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $209,375 | June 9, 2020 | May 31, 2022 | SWAIN, SUSAN L | reporter.nih.gov |
| The Host Genetics of Age-Dependent Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $205,083 | July 1, 2020 | June 30, 2023 | MENACHERY, VINEET D | reporter.nih.gov |
| Development of an influenza A virus and Aspergillus fumigatus coinfection model | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $205,000 | February 1, 2020 | January 31, 2023 | OBAR, JOSHUA J | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 | $203,611 | August 23, 2016 | March 31, 2022 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Determining the role of NLRP3 on the placement and protective potential of CD73+ BRMs post influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $202,725 | March 1, 2020 | February 28, 2022 | ALLIE, S RAMEEZA | reporter.nih.gov |
| Pan-vaccine Analysis to Test the Impact of Cytomegalovirus on Vaccine Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $201,875 | June 1, 2020 | May 31, 2022 | HU, ZICHENG | reporter.nih.gov |
| Antibody responses in humans after infection with avian influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $200,000 | January 10, 2017 | December 31, 2021 | KRAMMER, FLORIAN | reporter.nih.gov |
| TONSILS: AN UNRECOGNIZED ROLE IN INFLUENZA VIRUS EVOLUTION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $200,000 | August 4, 2022 | July 31, 2025 | OKDA, FATEN ABDELAAL | reporter.nih.gov |
| Influenza host specific glycan motif identification through systems biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $199,831 | January 31, 2020 | December 31, 2022 | WAN, XIUFENG HENRY | reporter.nih.gov |
| Interplay between respiratory syncytial virus and nucleotide biosynthesis pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $199,384 | February 7, 2020 | January 31, 2023 | FEARNS, RACHEL | reporter.nih.gov |
| Genetic susceptibility to mucosal infections with aging (Resubmission) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $199,375 | June 1, 2020 | May 31, 2023 | BOU GHANEM, ELSA | reporter.nih.gov |
| A Miniature Pig Model for the Study of Host-Immune Responses Against Influenza A Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $198,829 | July 15, 2020 | June 30, 2023 | SCHOTSAERT, MICHAEL | reporter.nih.gov |
| Role of T cell-derived amphiregulin in recovery from influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $197,940 | February 12, 2020 | January 31, 2023 | ARPAIA, NICHOLAS | reporter.nih.gov |
| ZFAND6 regulation of innate antiviral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $197,900 | March 16, 2020 | February 29, 2024 | HARHAJ, EDWARD W | reporter.nih.gov |
| Training Program Plan to Improve Intervention Research for Prevention of Childhood Pneumonia in Guatemala | NIH | Fogarty International Center | 2022 to 2023 | $196,969 | August 15, 2022 | March 31, 2025 | CORDON-ROSALES, CELIA | reporter.nih.gov |
| Bourbon virus: Therapy development and Serology | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $196,875 | March 13, 2020 | February 28, 2023 | BOON, ADRIANUS CM | reporter.nih.gov |
| Baloxavir Derivatives As Inhibitors of Hantavirus Endonuclease Activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $196,076 | March 9, 2020 | February 28, 2023 | MACKOW, ERICH R | reporter.nih.gov |
| A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $195,625 | July 12, 2021 | June 30, 2023 | PICKING, WENDY L. | reporter.nih.gov |
| Legionella-Polymorphonuclear Leukocytes Interaction | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $195,000 | June 17, 2020 | May 31, 2022 | ABU KWAIK, YOUSEF A | reporter.nih.gov |
| Invasive aspergillosis complicating severe influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $194,789 | June 4, 2020 | May 31, 2024 | NGUYEN, M. HONG THI | reporter.nih.gov |
| Genetically humanized mice for modeling human Fc-receptor interaction during influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $194,375 | March 3, 2020 | February 28, 2022 | KOLLER, BEVERLY H | reporter.nih.gov |
| Identifying Genetic Regulators and New Models of Wild Type Coronavirus Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $194,375 | June 2, 2020 | May 31, 2023 | GRALINSKI, LISA | reporter.nih.gov |
| Determining the mechanisms by which YesMN drives pneumococcal host-to-host transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,750 | June 10, 2020 | May 31, 2023 | ZAFAR, MUHAMMAD AMMAR | reporter.nih.gov |
| Evaluation of CC mice as an improved model for influenza immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,125 | March 2, 2020 | February 28, 2023 | HARTY, JOHN T | reporter.nih.gov |
| Broad Spectrum Anti-viral Compounds Targeting the SKI Complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,125 | June 5, 2020 | May 31, 2023 | FRIEMAN, MATTHEW BRYAN | reporter.nih.gov |
| RSV-induced inflammation in the brain | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $193,125 | September 2, 2020 | August 31, 2022 | VARGA, STEVEN M | reporter.nih.gov |
| Visualizing the resolution of innate immune responses during influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $192,500 | January 15, 2020 | December 31, 2021 | KIM, MINSOO | reporter.nih.gov |
| Alcohol inhibits anti-oxidant and immune defenses in the lung | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $191,430 | August 1, 2017 | July 31, 2024 | STAITIEH, BASHAR SAMIH | reporter.nih.gov |
| MECHANISMS REGULATING AVIAN INFLUENZA VIRUS INFECTIONS IN HUMANS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $190,882 | February 16, 2017 | January 31, 2022 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Utilization of the adjuvant effect of CRM197 protein to develop a trivalent protein-vaccine against Streptococcus pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $190,625 | March 1, 2022 | February 28, 2025 | KHAN, NADEEM | reporter.nih.gov |
| Mechanisms of GM-CSF-mediated metabolic regulation of monocyte function for control of pulmonary infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $189,274 | August 5, 2021 | July 31, 2023 | LIU, XIN | reporter.nih.gov |
| Elucidating the roles of alveolar macrophage inflammation and selfrenewal during influenza infection | NIH | National Institute on Aging | 2021 | $185,283 | August 15, 2020 | December 31, 2021 | SUN, JIE | reporter.nih.gov |
| Effect of vaping on COVID-19 infection | NIH | National Institute of Environmental Health Sciences | 2021 | $182,367 | September 30, 2016 | August 31, 2022 | WHITE, CARL W | reporter.nih.gov |
| Legacy of Obesity on Influenza and Coronavirus | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $182,000 | November 1, 2021 | October 31, 2023 | SCHULTZ-CHERRY, STACEY L | reporter.nih.gov |
| Macrophage and monocyte TBK1 function in host defense against influenza | NIH | National Heart, Lung, and Blood Institute | 2021 | $178,217 | April 9, 2019 | March 31, 2023 | HAGAN, ROBERT STEWART | reporter.nih.gov |
| Refining our understanding of antimicrobial peptide mediated disruption of the Klebsiella pneumoniae capsule | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $175,607 | August 24, 2021 | September 15, 2022 | FLEEMAN, RENEE | reporter.nih.gov |
| The Anti-Cyclic Citrullinated Protein Antibody Repertoire and Lung Involvement in Rheumatoid Arthritis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $174,645 | September 4, 2020 | August 31, 2024 | SOLOMON, JOSHUA | reporter.nih.gov |
| CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $174,459 | April 1, 2014 | May 31, 2022 | TREANOR, JOHN JAY | reporter.nih.gov |
| Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19 | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $167,496 | August 15, 2021 | August 14, 2023 | SHAPPELL, CLAIRE | reporter.nih.gov |
| Role of IL-22/IL-22RA2 during pneumococcal pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 | $167,292 | September 15, 2017 | June 30, 2023 | TREVEJO-NUNEZ, GIRALDINA | reporter.nih.gov |
| Characterizing clinical and biologic features of persistent hypoxemic respiratory failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $164,836 | May 16, 2021 | May 15, 2023 | SATHE, NEHA ALHAD | reporter.nih.gov |
| Developing a set of robust tools to interrogate Legionella effector function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $163,750 | November 23, 2020 | October 31, 2023 | O'CONNOR, TAMARA | reporter.nih.gov |
| Assessing Klebsiella pneumoniae invasion of the intact gut microbiome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $162,969 | August 5, 2021 | December 31, 2022 | VORNHAGEN, JAY | reporter.nih.gov |
| Development of Neutrophil-Avid Nanocarriers as an Antibiotic Delivery System | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $162,436 | July 6, 2020 | July 5, 2023 | RUBEY, KATHRYN | reporter.nih.gov |
| Pathophysiology of Influenza A Virus-induced Lung Injury in Juveniles | NIH | National Heart, Lung, and Blood Institute | 2021 | $161,229 | August 6, 2018 | April 30, 2023 | COATES, BRIA M | reporter.nih.gov |
| Carbonic anhydrase IX and pulmonary endothelial cell acidosis during infection | NIH | National Heart, Lung, and Blood Institute | 2021 | $160,067 | August 1, 2021 | December 31, 2021 | LEE, JI YOUNG | reporter.nih.gov |
| Giant MagnetoResistive (GMR) Sensors for Measuring Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $158,000 | August 1, 2020 | July 31, 2022 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| Functions of TBK1 in neutrophils during bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $155,500 | December 15, 2020 | November 30, 2022 | HAGAN, ROBERT STEWART | reporter.nih.gov |
| A scalable non-intrusive image annotation method using eye tracking for training deep learning models in radiology | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $152,500 | April 1, 2020 | January 31, 2023 | TASDIZEN, TOLGA | reporter.nih.gov |
| Inflammation and the Treatment of Primary Pneumonic Plague | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $152,000 | December 15, 2020 | November 30, 2023 | PECHOUS, ROGER D | reporter.nih.gov |
| Mechanistic Insights of TIMP-1 in Influenza Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $151,000 | May 1, 2022 | April 30, 2026 | WANG, XIAOYUN | reporter.nih.gov |
| SPMs, linoleic acid, and antibody levels in obesity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $149,471 | January 28, 2021 | December 31, 2023 | SHAIKH, SAAME R | reporter.nih.gov |
| High-throughput droplet qRT-PCR microfluidic platform for quantification of virus from single cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $146,021 | May 5, 2021 | August 15, 2022 | CHANG, CONNIE B | reporter.nih.gov |
| Sickness and Power: The Great North American Epizootic Flu of 1872 | NIH | National Library of Medicine | 2021 to 2023 | $144,837 | July 1, 2021 | September 30, 2024 | ANDREWS, THOMAS G | reporter.nih.gov |
| Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $140,000 | August 19, 2020 | July 31, 2022 | ROEMER, TERRY | reporter.nih.gov |
| An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $134,666 | June 6, 2023 | November 30, 2023 | MOUSA, JARROD | reporter.nih.gov |
| CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $131,053 | April 1, 2014 | May 20, 2022 | ROTHMAN, RICHARD | reporter.nih.gov |
| Metabolomics Evaluation of the Etiology of Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $128,250 | March 7, 2017 | February 28, 2024 | AMBROGGIO, LILLIAM | reporter.nih.gov |
| Dysfunction of microglial proteostasis drives neuroinflammation and cognitive decline following pneumonia | NIH | National Institute on Aging | 2021 to 2023 | $127,140 | February 1, 2021 | January 31, 2024 | GRANT, ROGAN AARON | reporter.nih.gov |
| Harnessing Natural Killer T cells to counteract swine influenza | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $126,076 | August 4, 2017 | December 31, 2021 | DRIVER, JOHN | reporter.nih.gov |
| Roles of tissue-resident helper T cells in mucosal immunity against influenza infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $124,441 | May 21, 2020 | December 31, 2021 | SUN, JIE | reporter.nih.gov |
| Discovery and characterization of protective Influenza Type B Virus neuraminidase antibodies | NIH | Office of the Director, National Institutes of Health | 2023 | $122,850 | September 1, 2023 | August 31, 2028 | WOLTERS, RACHAEL | reporter.nih.gov |
| Role of S-nitrosothiols in Akt1 signaling and pneumonia resolution | NIH | National Heart, Lung, and Blood Institute | 2021 | $118,157 | January 15, 2017 | September 19, 2021 | KRAFT, BRYAN D. | reporter.nih.gov |
| Adjuvant Discovery for Vaccines against Influenza Virus | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $112,821 | September 30, 2014 | August 31, 2023 | LEVY, OFER | reporter.nih.gov |
| Targeting metabolism to improve outcomes following severe influenza infection | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $111,005 | May 1, 2021 | December 1, 2023 | HUCKESTEIN, BRYDIE RYAN | reporter.nih.gov |
| Innate Lymphoid Cell Aging | NIH | National Institute on Aging | 2021 | $108,345 | September 30, 2017 | October 22, 2021 | YANG, QI | reporter.nih.gov |
| Probing the contribution of viral heterogeneity to interferon induction | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $108,000 | December 20, 2019 | November 30, 2022 | RUSSELL, ALISTAIR B | reporter.nih.gov |
| Lung-resident memory B cell development and function following influenza virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $108,000 | July 10, 2020 | June 30, 2022 | LAIDLAW, BRIAN | reporter.nih.gov |
| Evaluating seasonality of influenza in the tropics: Case study in Vietnam | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $104,731 | June 1, 2022 | December 31, 2023 | SERVADIO, JOSEPH | reporter.nih.gov |
| Investigating the development and clonal dynamics of broadly neutralizing B cells against influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $103,503 | July 22, 2021 | June 30, 2022 | GUTHMILLER, JENNA | reporter.nih.gov |
| Quantifying the genetic and environmental factors driving avian influenza spillover | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $95,010 | July 6, 2020 | March 31, 2022 | MONCLA, LOUISE HILLIER | reporter.nih.gov |
| Mechanisms of long-term maintenance of lung tissue-resident memory CD8 T cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $92,788 | January 1, 2021 | December 31, 2022 | LOBBY, JENNA L. | reporter.nih.gov |
| Biofilm-Facilitated Dissemination of Integrative Antibiotic Resistance Elements in Streptococcus pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $92,788 | September 1, 2021 | August 31, 2023 | ANTEZANA, BRENDA STEPHANIE | reporter.nih.gov |
| Development of reassortment-deficient influenza vaccine candidates: Rewiring packaging signals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $89,588 | September 1, 2019 | August 31, 2023 | ZHENG, ALLEN | reporter.nih.gov |
| Transitions Among Discrete Clinical States During ICU Stays in Patients with SARS-CoV-2 Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 | $85,550 | January 1, 2023 | December 31, 2023 | GAO, CATHERINE A. | reporter.nih.gov |
| Estimating the association between TNF inhibitors and Legionnaires' disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $84,117 | January 15, 2022 | August 27, 2023 | CASSELL, KELSIE | reporter.nih.gov |
| Adipose Tissue Inflammation in Influenza Infection Severity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $83,268 | September 1, 2022 | August 31, 2024 | ALARCON, PABLO | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Stanford University | Stanford, CA | 11 | $24.6 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 10 | $23 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 6 | $18.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 13 | $16.9 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 27 | $11.6 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 8 | $11.5 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 10 | $8.4 million | 0 | $0 |
| Washington University | Saint Louis, MO | 12 | $7.4 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 4 | $7.3 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 4 | $7 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 11 | $6.9 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 10 | $6.8 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 9 | $6.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 9 | $6.4 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 7 | $6 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 13 | $5.7 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 2 | $5.6 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 11 | $5.3 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 10 | $5.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 7 | $5.2 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 7 | $4.8 million | 0 | $0 |
| Duke University | Durham, NC | 7 | $4.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 6 | $4.2 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 4 | $4 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 3 | $3.9 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 5 | $3.9 million | 0 | $0 |
| Vaxess Technologies, Inc. | Cambridge, MA | 2 | $3.8 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 6 | $3.7 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 5 | $3.7 million | 0 | $0 |
| Arietis | Boston, MA | 1 | $3.6 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 4 | $3.5 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 4 | $3.5 million | 0 | $0 |
| Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center | Torrance, CA | 1 | $3.3 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 4 | $3.2 million | 0 | $0 |
| Yale University | New Haven, CT | 8 | $3.2 million | 0 | $0 |
| Emory University | Atlanta, GA | 10 | $3.1 million | 0 | $0 |
| Iowa State University | Ames, IA | 1 | $3.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 6 | $3.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 1 | $3.1 million | 0 | $0 |
| Trellis Bioscience, Inc. | Redwood City, CA | 2 | $3 million | 0 | $0 |
| Enepret, Inc. | Lexington, KY | 1 | $3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 3 | $2.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 5 | $2.9 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 5 | $2.9 million | 0 | $0 |
| University of Rochester | Rochester, NY | 7 | $2.8 million | 0 | $0 |
| Cytoagents, Inc. | Pittsburgh, PA | 2 | $2.8 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 6 | $2.7 million | 0 | $0 |
| Flugen, Inc. | Madison, WI | 1 | $2.6 million | 0 | $0 |
| Vaxnewmo, LLC | Saint Louis, MO | 2 | $2.6 million | 0 | $0 |
| Mucommune, LLC | Morrisville, NC | 2 | $2.5 million | 0 | $0 |
| Prokaryotics, Inc. | Union, NJ | 3 | $2.5 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 5 | $2.5 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 2 | $2.5 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 3 | $2.4 million | 0 | $0 |
| University of Melbourne | Melbourne | 1 | $2.4 million | 0 | $0 |
| Western Michigan Univ School of Medicine | Kalamazoo, MI | 2 | $2.3 million | 0 | $0 |
| Eldec Pharmaceuticals, Inc. | Durham, NC | 2 | $2.2 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 1 | $2.2 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 2 | $2.2 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 3 | $2.2 million | 0 | $0 |
| Southern Research Institute | Birmingham, AL | 1 | $2.2 million | 0 | $0 |
| University of Colorado at Boulder | Boulder, CO | 3 | $2.1 million | 0 | $0 |
| Texas Tech University | Lubbock, TX | 1 | $2 million | 0 | $0 |
| Inhalon Biopharma, Inc. | Morrisville, NC | 1 | $2 million | 0 | $0 |
| Sivec Biotechnologies, LLC | Fort Collins, CO | 1 | $2 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 4 | $2 million | 0 | $0 |
| Pharmain Corporation | Bothell, WA | 1 | $2 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 3 | $2 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 2 | $1.9 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 2 | $1.9 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 2 | $1.9 million | 0 | $0 |
| University of California at Davis | Davis, CA | 4 | $1.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 5 | $1.8 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 4 | $1.8 million | 0 | $0 |
| University of North Dakota Main Campus | Grand Forks, ND | 4 | $1.8 million | 0 | $0 |
| Abcombi Biosciences, Inc. | Amherst, NY | 1 | $1.8 million | 0 | $0 |
| Quanterix Corporation | Billerica, MA | 1 | $1.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 1 | $1.7 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 1 | $1.6 million | 0 | $0 |
| Access to Advanced Health Institute | Seattle, WA | 1 | $1.6 million | 0 | $0 |
| Oklahoma Medical Research Foundation | Oklahoma City, OK | 2 | $1.6 million | 0 | $0 |
| Baebies, Inc. | Durham, NC | 1 | $1.5 million | 0 | $0 |
| Texas A&M University | College Station, TX | 1 | $1.5 million | 0 | $0 |
| Codagenix, Inc. | Farmingdale, NY | 1 | $1.5 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 2 | $1.5 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 2 | $1.4 million | 0 | $0 |
| Harvard University | Cambridge, MA | 1 | $1.4 million | 0 | $0 |
| University of Louisville | Louisville, KY | 3 | $1.4 million | 0 | $0 |
| Cornell University | Ithaca, NY | 2 | $1.4 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 4 | $1.4 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $1.3 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $1.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 4 | $1.3 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 1 | $1.3 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 1 | $1.3 million | 0 | $0 |
| University of Tennessee Health Sci CTR | Memphis, TN | 2 | $1.3 million | 0 | $0 |
| University of Rhode Island | Kingston, RI | 2 | $1.3 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 1 | $1.2 million | 0 | $0 |
| University of Montana | Missoula, MT | 1 | $1.2 million | 0 | $0 |
| Carnegie Mellon University | Pittsburgh, PA | 1 | $1.2 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 4 | $7,603,728 | 0 | $0 |
| 2024 | 4 | $8,954,244 | 0 | $0 |
| 2023 | 184 | $80,712,015 | 0 | $0 |
| 2022 | 328 | $147,083,786 | 0 | $0 |
| 2021 | 424 | $192,458,962 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 357 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 357 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 357 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.